Federal Register #2026-17429

DEA Temporary Scheduling of Synthetic Opioids Mitragynine Pseudoindoxyl, MGM-15, and MGM-16

This DEA regulatory action temporarily places three potent synthetic opioids in Schedule I to address public health risks. - Government Buyer: - Department of Justice, Drug Enforcement Administration (DEA) - Substances Scheduled: - Mitragynine pseudoindoxyl - MGM-15 (dihydro-7-hydroxymitragynine) - MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine) - Includes all isomers, esters, ethers, salts, and related forms - No OEMs or commercial vendors are involved - No products or services are being procured - Notable Requirements: - Strict controls on handling, distribution, and possession - DEA registration required for authorized handling - Unauthorized possession or distribution prohibited - Substances are marketed in flavored chewable tablets and liquids - Action taken due to high abuse potential, addiction, and overdose risks - Period of Performance: - Temporary scheduling effective for two years, with possible one-year extension - Public comment is invited via regulations.gov

Description

This is a temporary scheduling order by the Justice Department and Drug Enforcement Administration to place mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I controlled substances. The order is effective from August 26, 2026, until August 26, 2028, and imposes controls and sanctions on handling these substances. The scheduling is based on findings that it is necessary to avoid imminent hazard to public safety. Comments on the order can be submitted via regulations.gov.

View original listing